Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

AC Immune Reports Progress AC Immune reported that ACI-19764 reached the cerebrospinal fluid around the brain and dose-dependently suppressed the inflammatory signal IL-1β in blood analysis. On August 20, AC Immune published interim data from the first cohorts of the ACI-19764 study in healthy volunteers. The company checked if the drug reached the central nervous system environment, achieved the necessary concentration there, and was associated with a biochemical response in the blood. The ACI-19764 is an orally administered small chemical compound. AC Immune is developing it as an NLRP3-inflammasome inhibitor - an intracellular complex of the immune system involved in the formation of inflammatory signals, including IL-1β. In the August 20 release, the company reported on cohorts with single and repeated doses. The detection of ACI-19764 in cerebrospinal fluid shows that the drug reached the central nervous system environment. Daily doses of up to 10 mg gave concentrations above the IC90 level - the level of substance that in a laboratory test suppresses 90% of the chosen response. In whole blood samples, IL-1β release decreased with increasing dose. These measurements answer different questions: did the drug reach the central nervous system environment, is its concentration sufficient for the laboratory goal, and does IL-1β release in the blood decrease with dose. The original protocol in the NCT07463196 registry is designed for 78 healthy volunteers. 🔗 Read original →